DELFI Diagnostics Receives New York State Approval for Lung Cancer Blood Test
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read More
Search Results for: lung cancer
FDA Approves Companion Diagnostic to Identify NSCLC Patients Eligible for Tepmetko
The tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read More
Medicare Expands Coverage for Cancer Immunotherapy Monitoring Test
CMS has expanded Medicare coverage for Personalis’ NeXT Personal MRD test, now allowing immunotherapy monitoring in late-stage solid tumor patients, supported by recent clinical evidence from Vall d’Hebron Institute of Oncology.
Read More
Labs Say They’re Automated. The Workflow Tells a Different Story
Many labs consider themselves automated, but manual steps persist. Here’s where automation is working, where it’s falling short, and how some labs are starting to close the gaps.
Read More
New Clinical Data Supports Blood-Based Monitoring for Cancer Treatment Response
Personalis presented data at AACR showing its NeXT Personal assay enabled ultrasensitive ctDNA monitoring for colorectal and lung cancer patients, demonstrating 100% sensitivity at baseline and 100% specificity for relapse post-surgery.
Read More